Is Praluent a Statin?
No, Praluent (alirocumab) is not a statin—it is a fully human monoclonal antibody that inhibits PCSK9, representing an entirely different drug class with a distinct mechanism of action from statins. 1
Mechanism of Action
Alirocumab works by binding to proprotein convertase subtilisin kexin type 9 (PCSK9), preventing PCSK9 from binding to LDL receptors on hepatocytes. 1 This mechanism differs fundamentally from statins, which inhibit HMG-CoA reductase to reduce cholesterol synthesis in the liver. By blocking PCSK9, alirocumab increases the number of LDL receptors available to clear LDL cholesterol from the blood, thereby lowering LDL-C levels by 50-65%. 2
Drug Classification
- Alirocumab is classified as a PCSK9 inhibitor monoclonal antibody (IgG1 isotype), not a statin. 1
- It is produced by recombinant DNA technology and consists of two disulfide-linked human heavy chains, each covalently linked to a human kappa light chain, with an approximate molecular weight of 146 kDa. 1
- The drug is administered as a subcutaneous injection every 2 weeks (75 mg or 150 mg), unlike statins which are oral medications taken daily. 1, 3
Clinical Role Relative to Statins
Alirocumab is approved as an adjunct to diet and maximally tolerated statin therapy, not as a replacement for statins. 1, 4 The American Heart Association recommends PCSK9 inhibitors for:
- Patients with familial hypercholesterolemia on maximally tolerated statin therapy 2
- Patients with established atherosclerotic cardiovascular disease who cannot achieve >50% LDL-C reduction with statins 2
- Statin-intolerant patients at high cardiovascular risk, where alirocumab serves as an alternative rather than an adjunct 5, 2
Key Distinguishing Features
- Alirocumab does not cause the muscle-related adverse events typical of statins. In the ODYSSEY ALTERNATIVE trial, alirocumab had fewer skeletal muscle-related adverse events (32.5%) compared to atorvastatin (46%) in statin-intolerant patients. 5
- Unlike statins, alirocumab is not metabolized by cytochrome P450 enzymes—it degrades to small peptides and amino acids as a protein therapeutic. 1
- Alirocumab provides additional benefits beyond LDL-C reduction, including a 25% reduction in lipoprotein(a), which statins do not significantly affect. 2
Common Clinical Pitfall
A critical error is assuming that because alirocumab is used "with statins" it must be a statin itself. The evidence clearly demonstrates that alirocumab belongs to an entirely separate therapeutic class (monoclonal antibodies targeting PCSK9) and is used in combination with statins precisely because it works through a complementary mechanism. 5